Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

1.0K
Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
1.0K
Pharmacokinetic Models: Comparison and Selection Criterion01:26

Pharmacokinetic Models: Comparison and Selection Criterion

490
Physiological and compartmental models are valuable tools used in studying biological systems. These models rely on differential equations to maintain mass balance within the system, ensuring an accurate representation of the dynamic processes at play.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
490
Dosage Regimen: Individualization01:24

Dosage Regimen: Individualization

398
Individualization in dosing regimens is the customization of medication doses for individual patients. Its necessity arises from the goal of maximizing therapeutic benefits while minimizing risks. This approach is pivotal because human responses to drugs can vary widely; what is effective for one person may be inadequate or excessive for another. Interpatient (intersubject) variability refers to differences in drug responses between individuals, while intrapatient (intrasubject) variability...
398
Dosage Regimens: Partial Pharmacokinetic Parameters01:01

Dosage Regimens: Partial Pharmacokinetic Parameters

363
It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
363
Pharmacokinetic Models: Overview01:20

Pharmacokinetic Models: Overview

2.6K
Pharmacokinetic models utilize mathematical analysis to achieve a detailed quantitative understanding of a drug's life cycle within the body. They are instrumental in simulating a drug's pharmacokinetic parameters, predicting drug concentrations over time, optimizing dosage regimens, linking concentrations with pharmacologic activity, and estimating potential toxicity.
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal...
2.6K
Determination of Multiple Dosing Parameters: Loading and Maintenance Doses01:25

Determination of Multiple Dosing Parameters: Loading and Maintenance Doses

394
A loading dose is an essential pharmacological strategy to rapidly achieve the target plasma drug concentration necessary for an immediate therapeutic effect. This approach is especially critical for drugs characterized by slow absorption or extended half-lives, where delaying therapeutic plasma levels could compromise treatment outcomes. By administering a loading dose, clinicians ensure a prompt onset of drug action, even for agents with complex pharmacokinetic profiles.Achieving steady-state...
394

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Evaluating Patient Medians for Laboratory Quality Control Using Long-Term Carbamazepine Monitoring Data.

The journal of applied laboratory medicine·2026
Same author

Genomic Medicine Sweden: Advancing precision medicine at the national level.

Journal of internal medicine·2026
Same author

Informing Sampling Design for Lung Distribution Studies Using a Pulmonary Population Minimal PBPK Model.

Clinical pharmacokinetics·2026
Same author

Evaluating neoantigen-vaccine responses through mechanistic and model-based frameworks.

NPJ precision oncology·2026
Same author

Risk of venous thromboembolism after SARS-CoV-2 vaccination-Evidence from genome-wide association study and population-based observational study.

British journal of clinical pharmacology·2026
Same author

HLA-B*44 Alleles and HLA-DQA1*03:01 as Genetic Risk Factors for Drug-Induced Liver Injury due to Fluoroquinolones.

Liver international : official journal of the International Association for the Study of the Liver·2026

Related Experiment Video

Updated: May 4, 2026

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
08:13

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Published on: September 30, 2021

7.0K

Characterizing variability in warfarin dose requirements in children using modelling and simulation.

Anna-Karin Hamberg1, Mia Wadelius, Lena E Friberg

  • 1Department of Medical Sciences, Clinical Pharmacology, Uppsala University, Uppsala, Sweden.

British Journal of Clinical Pharmacology
|December 17, 2013
PubMed
Summary

Genetic and clinical factors significantly influence warfarin dosing in children, similar to adults. This study quantifies these factors to enable more personalized and safer warfarin therapy for pediatric patients.

Keywords:
PKPD modellingdose variabilitypaediatricspharmacogeneticspharmacometricswarfarin

More Related Videos

Comprehensive Analysis of Drug Response using the FLICK Assay
09:42

Comprehensive Analysis of Drug Response using the FLICK Assay

Published on: June 6, 2025

859
Description of a Swine Infant Model of Volume-Controlled Hemorrhagic Shock
09:09

Description of a Swine Infant Model of Volume-Controlled Hemorrhagic Shock

Published on: November 3, 2023

2.1K

Related Experiment Videos

Last Updated: May 4, 2026

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
08:13

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Published on: September 30, 2021

7.0K
Comprehensive Analysis of Drug Response using the FLICK Assay
09:42

Comprehensive Analysis of Drug Response using the FLICK Assay

Published on: June 6, 2025

859
Description of a Swine Infant Model of Volume-Controlled Hemorrhagic Shock
09:09

Description of a Swine Infant Model of Volume-Controlled Hemorrhagic Shock

Published on: November 3, 2023

2.1K

Area of Science:

  • Pharmacogenomics
  • Pediatric pharmacology
  • Drug dosing optimization

Background:

  • Inter-individual variability in warfarin dose is substantial in adults, influenced by genetic, clinical, and demographic factors.
  • Causes of warfarin dose variability in children remain less understood compared to adults.

Purpose of the Study:

  • To identify and quantify major genetic, clinical, and demographic factors affecting warfarin dose variability in children.
  • To update and optimize an adult pharmacometric warfarin model for pediatric use.

Main Methods:

  • Utilized clinical, demographic, and genetic data from 163 children.
  • Applied pharmacometric modeling and simulation to an updated adult warfarin model.
  • Analyzed over 183 years of warfarin therapy and 6445 INR observations.

Main Results:

  • CYP2C9 genotype explained up to a four-fold dose difference; VKORC1 genotype explained up to a two-fold dose difference.
  • Non-linear relationship observed between bodyweight and warfarin dose.
  • Age, baseline/target INR, and time since therapy initiation significantly impacted pediatric warfarin dose, unlike CYP4F2 genotype.

Conclusions:

  • The updated model quantifies key factors influencing pediatric warfarin dose variability.
  • This knowledge can facilitate the development of individualized dosing regimens.
  • Improved efficacy and safety of warfarin therapy in children can be pursued through prospective evaluation of optimized regimens.